With the FLEXcyte technology co-developed by innoVitro and Nanion Technologies we offer true contractility measurements. It is based on a biohybrid cardiac muscle tissue from human stem cell-derived cardiac muscle cells and high-precision, ultra-thin and hyperelastic silicone membranes. Together they reflect the properties of real heart tissue in unprecedented quality and reproducibility. The physiological mechanical conditions support maturation of the cells and physiological response to positive inotropic agents. The 96-well format enables higher throughput in vitro at lower costs. Therefore, you can get functional information on your drug candidates faster and cheaper.
The predecessor of the technology has been developed at the University of Applied Sciences Aachen since 2001 under the name CellDrum, but for a long time it has been used exclusively for academic purposes. As part of the doctoral thesis by Matthias Goßmann, one of the founders of innoVitro, it was further developed into an industrial demonstrator and validated on a wide range of pharmacological agents.
Compared to existing solutions, the FLEXcyte technology offers both the scalability to high throughput as well as the physiological environment for the cells. This makes in vitro contractility measurements viable for the pharmaceutical industry, which is exposed to increasing governmental regulation of animal experiments.
The technology provides information about the key features of cardiac contraction:
- contraction amplitude
- beat rate
- beat shape for up- and downstroke
- arrhythmic events
September 23 – 26, 2019
Meet us at the SPS annual meeting in Barcelona